Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Cadence Pharmaceuticals
August 11, 2015
Mallinckrodt buys cancer cell therapy for $1.3bn
April 10, 2014
Q1 M&A data underline strong sentiment in life science sector
April 08, 2014
Mallinckrodt dashes hopes of a return to valuation fundamentals
February 12, 2014
Mallinckrodt pays through the nose for popularity
December 03, 2012
Cadence seeks to put Ofirmev patent worries to rest
May 11, 2012
First quarter data reveal new drug launches remain challenging
January 06, 2012
Investors buoyed by signs of speedier drug launches
May 11, 2011
Tough quarter for new product launches by small pharma groups
May 04, 2011
Event – Spotlight on new product launches for small pharma companies going solo
February 14, 2011
Cadence needs fast-paced Ofirmev launch to build confidence
January 10, 2011
Failure to launch for 2010's big hopes
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
January 17, 2023
JP Morgan Healthcare Conference 2023
January 12, 2023
Evaluate Vantage 2023 Preview Infographic
Editor's Picks
January 03, 2023
The biggest-selling pharma companies of 2023
January 05, 2023
The biggest-selling drugs of 2023
January 05, 2023
Flotations fail to bounce back
January 06, 2023
Fate runs out of excuses
December 15, 2022
Ash 2022 roundup
